There are two clear market leaders in the market for obesity drugs. Novo Nordisk and Eli Lilly are the only pharmaceutical companies with GLP-1 medications approved for weight loss, and the ...

LONDON, April 25 (Reuters Breakingviews) - The pecking order of the obesity drug market is shifting. Eli Lilly (LLY.N), opens new tab, the $815 billion maker of blockbuster weight-loss drugs ...

Doncaster, Stockton-on-Tees, and Walsall are among the areas where obesity prevalence has climbed above 33.3 per cent in 2023/24. Just five years prior, these areas, along with others like Durham ...

Cantor sees Eli Lilly reaching over 85% obesity market share by 2029–2030. Orforglipron lowered A1C by 1.3%–1.6% from baseline in Phase 3 ACHIEVE-1 trial. Feel unsure about the market’s next ...

Pfizer has made competing in the obesity market central to its post-Covid comeback plan. As demand for coronavirus vaccines and therapies ebbs, the business of selling weight-loss treatments has ...

based largely on booming sales of their diabetes and obesity products. With their surges over the last few years, Lilly and Novo have become the drugmakers with the largest market caps in the U.S ...

Obesity rates are surging in several areas across England, according to new data, notably in the Midlands and North East. An estimated one-third or more of adults in 44 local authorities are now ...

Obesity rates are surging in several areas across England, according to new data, notably in the Midlands and North East. An estimated one-third or more of adults in 44 local authorities are now ...

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant. The company said Monday the stoppage comes after it ...

Pfizer’s danuglipron could have been a convenient alternative in the lucrative weight-loss drug market, currently dominated ... starting block as its other obesity drugs are all in the early ...